TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03046069

Intervention type: OTHER
Intervention: Telephone interviews
Description: Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.

Intervention type: OTHER
Intervention: In-person focus groups
Description: Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.

Intervention type: OTHER
Intervention: DCE surveys- cognitive interviews
Description: Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.

Intervention type: OTHER
Intervention: Modified DCE
Description: The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.

Intervention type: OTHER
Intervention: Online DCE survey
Description: An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
Study: NCT02014285

Intervention type: PROCEDURE
Intervention: Muscle Ultrasound and Muscle Sample
Description: The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
Study: NCT04383743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT03128346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: IV, fentanyl
Study: NCT03193931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate Injectable Solution
Description: Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
Study: NCT01662518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexamethasone drug delivery system (DDS-25)
Description: 350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
Study: NCT03318250

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Root Ganglion Stimulation
Description: During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Root Ganglion Stimulation
Description: During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
Study: NCT01127412

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity stimulating program
Study: NCT00878527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CircuLite Synergy Pocket Circulatory Assist Device
Description: Goal of successful implantation and follow-up for at least three months
Study: NCT02977988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain and Recovery (B&R)
Description: B\&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B\&R group will receive didactic education on the neurobiology of addiction. B\&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
Study: NCT00674661

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVA Irradiation
Description: UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Study: NCT02432534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.

Intervention type: OTHER
Group type: OTHER
Intervention: UVB
Description: The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
Study: NCT03016286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: Whole body vibration at 25Hz frequency
Study: NCT01968668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 1.25 mg BAY94-8862 tablet once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 2.5 mg BAY94-8862 tablet once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 5 mg BAY94-8862 tablet once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 7.5 mg BAY94-8862 tablet once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 10 mg BAY94-8862 tablet once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 94-8862
Description: 15 mg BAY 94-8862 tablet once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 94-8862
Description: 20 mg BAY 94-8862 tablet once daily in the morning
Study: NCT01053819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
Study: NCT01552252

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: apple juice
Description: unaltered(0% POs-Ca) commercially available apple juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apple juice with 0.5% POs-Ca
Description: Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apple juice with 1% POs-Ca
Description: Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apple juice with 1.5% POs-Ca
Description: Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apple juice with 2% POs-Ca
Description: Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
Study: NCT00276159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 852A
Description: Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
Study: NCT00946959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Description: A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
Study: NCT01477840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
Study: NCT03762109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: muscle relaxant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: inactive pill
Study: NCT03012347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BullFrog Gel Sunscreen Land Sport SPF-50
Description: Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
Study: NCT02426892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA 101
Description: 100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
Study: NCT02053467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Champlain BASE eConsult Service
Description: After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
Study: NCT01832870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sipuleucel-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Study: NCT01035203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Endurance exercise 3 times weekly for 45 minutes, 4 weeks long

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: Teaching of techniques to reduce fatigue and to improve stamina
Study: NCT00487851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: hepaticojejunostomy and gastroenterostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic strategy
Description: Stent insertion
Study: NCT04383743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study: NCT03178773

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TExT-MED
Description: messages designed to inspire motivation and behavior change

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TExT-MED
Description: messages designed to inspire motivation and behavior change

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FANS
Description: SMS delivered messages to family members to improve social support
Study: NCT00356369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal ACWY (vaccine)
Description: One intramuscular dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACWY
Description: One subcutaneous dose.
Study: NCT03184415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC20155
Description: tablet
Study: NCT00240565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tositumomab 450 mg
Description: Unlabeled TST
Study: NCT03184415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20155
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20156
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC20156
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of DWC20155
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of DWC20155
Description: tablet
Study: NCT00240565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tositumomab 35 mg
Description: TST labeled with 185 megaBecqueral (mbq) of iodine 131
Study: NCT04251780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug treatment of Hyperaldosteronism
Description: Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
Study: NCT04108715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plain block for mastectomy analgesia
Description: After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
Study: NCT03184415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of DWC20155
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of DWC20156
Description: tablet
Study: NCT01271660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering
Study: NCT06231212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECa 233
Description: Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen group was given capsules containing 200 mg of ibuprofen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-controlled group received capsules containing 250 mg of lactose
Study: NCT01876342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open repair
Description: 2-0 sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic TEP repair
Description: mesh
Study: NCT04034381

Intervention type: OTHER
Intervention: No intervention (descriptive survey only)
Description: No intervention

Intervention type: OTHER
Intervention: No intervention (descriptive survey only)
Description: No intervention
Study: NCT04383743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04108715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep serratus anterior plane block
Description: After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
Study: NCT03671408

Intervention type: OTHER
Intervention: clinical measurements
Description: only clinical parameters were recorded

Intervention type: OTHER
Intervention: clinical measurements
Description: only clinical parameters were recorded
Study: NCT01811602

Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
Study: NCT00926133

Intervention type: OTHER
Intervention: OGTT
Description: Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
Study: NCT02557113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cavuplasty
Description: Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
Study: NCT01752400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Study: NCT01974752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75mg selumetinib
Description: selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dacarbazine
Description: dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
Study: NCT01766895

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling of viral hepatitis to determined seroprevalence in uremic patients
Study: NCT00393302

Intervention type: PROCEDURE
Intervention: HIV screening in pregnancy
Study: NCT02010736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single treadmill gait training with additional loading
Study: NCT01369082

Intervention type: DRUG
Intervention: Maintenance Immunosuppressive Treatment
Description: All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.